Skip to Content

Famciclovir Pregnancy and Breastfeeding Warnings

Famciclovir is also known as: Famvir

Famciclovir Pregnancy Warnings

Famciclovir was tested on embryo-fetal development in rats and rabbits at oral doses up to 1000 mg/kg/day; IV doses of 360 mg/kg/day in rats and 120 mg/kg/day in rabbits were also tested. No adverse effects were observed on embryo-fetal development. To monitor maternal-fetal outcomes of pregnant women exposed to famciclovir a pregnancy registry has been established. Physicians are encouraged to register their patients at 888-669-6682.

Famciclovir has been assigned to pregnancy category B. Animal studies failed to reveal evidence of teratogenicity. There are no controlled data in human pregnancy. Famciclovir should only be given during pregnancy when need has been clearly established.

See references

Famciclovir Breastfeeding Warnings

There are no data on the excretion of famciclovir into human milk. Following oral administration of famciclovir to lactating rats, its active metabolite penciclovir was excreted in breast milk at concentrations higher than those seen in the plasma. There are no data on the safety of penciclovir in nursing infants. The manufacturer recommends that famciclovir should not be administered to nursing women unless the benefit outweighs the risk. The U.S. Public Health Service Centers for Disease Control and Prevention advise HIV-infected mothers not to breast-feed to avoid postnatal transmission of HIV to a child who may not yet be infected.

See references

References for pregnancy information

  1. "Product Information. Famvir (famciclovir)." SmithKline Beecham, Philadelphia, PA.

References for breastfeeding information

  1. "Product Information. Famvir (famciclovir)." SmithKline Beecham, Philadelphia, PA.
  2. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. National Institute of Health "Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available from: URL:" ([2011 Sep 14]):
  3. "Infant feeding and transmission of human immunodeficiency virus in the United States." Pediatrics 131 (2013): 391-6

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.